Involvement of protein kinase C α and δ activities on the induction of the retinoic acid system in mammary cancer cells

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 1110-1121

  Berardi, Damián E ^a   Bessone, María I Díaz ^a   Motter, Andrea ^b   Bal de Kier Joffé, Elisa D ^a   Urtreger, Alejandro J ^a   Todaro, Laura B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

Author keywords

Mammary cancer; PKC; Retinoic acid receptors

Indexed keywords

PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; RETINOIC ACID; RETINOIC ACID RECEPTOR; ISOPROTEIN; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL DIFFERENTIATION; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; METABOLISM; MOUSE; NUCLEOLUS; TUMOR CELL CULTURE;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL NUCLEOLUS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN ISOFORMS; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RECEPTORS, RETINOIC ACID; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84941739406     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22181     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
3. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011; 6:345-364.
4. Chambon P. The retinoid signaling pathway: Molecular and genetic analyses. Semin Cell Biol 1994; 5:115-125.
5. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 1995; 83:859-869.
6. Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta 2011; 1812:1023-1031.
7. Lee HY, Walsh GL, Dawson MI, Hong WK, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways. J Biol Chem 1998; 273:7066-7071.
8. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58:3163-3172.
9. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85:403-414.
10. Chen JY, Penco S, Ostrowski J, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J 1995; 14:1187-1197.
11. Cho Y, Tighe AP, Talmage DA. Retinoic acid induced growth arrest of human breast carcinoma cells requires protein kinase C alpha expression and activity. J Cell Physiol 1997; 172:306-313.
12. Carter CA, Parham GP, Chambers T. Cytoskeletal reorganization induced by retinoic acid treatment of human endometrial adenocarcinoma (RL95-2) cells is correlated with alterations in protein kinase C-alpha. Pathobiology 1998; 66:284-292.
13. Dekker LV, Parker PJ. Regulated binding of the protein kinase C substrate GAP-43 to the V0/C2 region of protein kinase C-delta. J Biol Chem 1997; 272:12747-12753.
14. Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ. Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog 2007; 46:381-390.
15. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332:281-292.
16. Edwards AS, Newton AC. Regulation of protein kinase C betaII by its C2 domain. Biochemistry 1997; 36:15615-15623.
17. Newton AC. Protein kinase C: Structure, function, and regulation. J Biol Chem 1995; 270:28495-28498.
18. Nakashima S. Protein kinase C alpha (PKC alpha): Regulation and biological function. J Biochem 2002; 132:669-675.
19. Lahn M, Kohler G, Sundell K, et al. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004; 67:1-10.
20. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006; 25:3286-3295.
21. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010; 9:76-89.
22. Fujii T, Nakamura AM, Yokoyama G, et al. Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells. Oncol Rep 2005; 14:489-494.
23. Kiley SC, Clark KJ, Duddy SK, Welch DR, Jaken S. Increased protein kinase C delta in mammary tumor cells: Relationship to transformtion and metastatic progression. Oncogene 1999; 18:6748-6757.
24. Lonne GK, Masoumi KC, Lennartsson J, Larsson C. Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J Biol Chem 2009; 284:33456-33465.
25. Vucenik I, Ramakrishna G, Tantivejkul K, Anderson LM, Ramljak D. Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 2005; 91:35-45.
26. Urtreger A, Ladeda V, Puricelli L, et al. Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two new murine mammary tumor cell lines. Int J Oncol 1997; 11:489-496.
27. Puricelli L, Proietti CJ, Labriola L, et al. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int J Cancer 2002; 100:642-653.
28. Callero MA, Loaiza-Perez AI. The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. Int J Breast Cancer 2011; 2011:923250.
29. Zelent A. PCR cloning of N-terminal RAR isoforms and APL-associated PLZF-RAR alpha fusion proteins. Methods Mol Biol 1998; 89:307-332.
30. Grossoni VC, Todaro LB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ. Opposite effects of protein kinase C beta1 (PKCbeta1) and PKCepsilon in the metastatic potential of a breast cancer murine model. Breast Cancer Res Treat 2009; 118:469-480.
31. Leskow FC, Krasnapolski MA. Urtreger AJ The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients. Curr Pharm Biotechnol 2011; 12:1961-1973.
32. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17:1065-1071.
33. Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2011; 9:1664-1670.
34. Tighe AP, Talmage DA. Retinoids arrest breast cancer cell proliferation: Retinoic acid selectively reduces the duration of receptor tyrosine kinase signaling. Exp Cell Res 2004; 301:147-157.
35. Kahl-Rainer P, Marian B. Retinoids inhibit protein kinase C-dependent transduction of 1, 2-diglyceride signals in human colonic tumor cells. Nutr Cancer 1994; 21:157-168.
36. Kambhampati S, Li Y, Verma A, et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003; 278:32544-32551.
37. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 2011; 12:496-503.
38. Radominska-Pandya A, Chen G, Czernik PJ, et al. Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem 2000; 275:22324-22330.
39. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010; 62:1285-1298.
40. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005; 4:477-486.
41. Yamada O, Ozaki K, Nakatake M, et al. Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells. Histochem Cell Biol 2010; 134:555-563.
42. Desai DS, Hirai S, Karnes WE Jr, Niles RM, Ohno S. Cloning and characterization of the murine PKC alpha promoter: Identification of a retinoic acid response element. Biochem Biophys Res Commun 1999; 263:28-34.
43. Hoyos B, Imam A, Chua R, et al. The cysteine-rich regions of the regulatory domains of Raf and protein kinase C as retinoid receptors. J Exp Med 2000; 192:835-845.
44. Imam A, Hoyos B, Swenson C, et al. Retinoids as ligands and coactivators of protein kinase C alpha. FASEB J 2001; 15:28-30.
45. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31:817-899.
46. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P. Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR.RARalpha heterodimerization and transcriptional activity. J Biol Chem 1999; 274:38225-38231.
47. Rochette-Egly C, Gaub MP, Lutz Y, Ali S, Scheuer I, Chambon P. Retinoic acid receptor-beta: Immunodetection and phosphorylation on tyrosine residues. Mol Endocrinol 1992; 6:2197-2209.
48. Gomel R, Xiang C, Finniss S, et al. The localization of protein kinase Cdelta in different subcellular sites affects its proapoptotic and antiapoptotic functions and the activation of distinct downstream signaling pathways. Mol Cancer Res 2007; 5:627-639.
49. Uddin S, Sassano A, Deb DK, et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002; 277:14408-14416.
50. Piskunov A, Rochette-Egly C. A retinoic acid receptor RARalpha pool present in membrane lipid rafts forms complexes with G protein alphaQ to activate p38MAPK. Oncogene 2012; 31:3333-3345.